However, about 10-15% of CML patients develop resistance to imatinib, which led to the development of other generations of TKIs, such as dasatinib and Nilotinib, including clonal evolution, mutations in the BCR::ABL1 kinase domain, and activation of BCR::ABL1 independent pathways (46–48). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.